EFFECT OF ESCALATED DOSE THERAPY OF INTERFERON ALFA-2B ON HEPATITIS-C PATIENTS

被引：0
|
作者：
PRASAD, S
WATERS, B
PORTERA, FA
SMALLEY, DL
KARAS, JG
RIELY, CA
机构：
[1] UNIV TENNESSEE CTR HLTH SCI,DIV GASTROENTEROL,MEMPHIS,TN 38163
[2] UNIV TENNESSEE CTR HLTH SCI,DEPT MED,MEMPHIS,TN 38163
[3] UNIV TENNESSEE CTR HLTH SCI,DEPT PATHOL,MEMPHIS,TN 38163
来源：
CLINICAL RESEARCH | 1992年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：A840 / A840
页数：1
相关论文
共 50 条
  • [21] COMPARATIVE EFFICACY OF HIGH AND LOW-DOSE OF INTERFERON ALFA-2B IN CHRONIC HEPATITIS-C - A RANDOMIZED CONTROLLED TRIAL
    TASSOPOULOS, NC
    KARVOUNTZIS, G
    TOULOUMI, G
    DELLADETSIMA, J
    PAPATHEODORIDIS, GV
    KATSOULIDOU, A
    RETALIS, G
    HATZAKIS, A
    HEPATOLOGY, 1995, 22 (04) : 32 - 32
  • [22] Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
    Poynard, T
    Ratziu, V
    McHutchison, J
    Manns, M
    Goodman, Z
    Zeuzem, S
    Younossi, Z
    Albrecht, J
    HEPATOLOGY, 2003, 38 (01) : 75 - 85
  • [23] Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin
    Kraus, MR
    Schäfer, A
    Wissmann, S
    Reimer, P
    Scheurlen, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) : 90 - 100
  • [24] Interferon alfa-2b and ribavirin in patients with resistant chronic hepatitis C.
    Min, AD
    Jones, JL
    Jacobson, IM
    Klion, FM
    Goldman, IS
    Esposito, S
    Geders, JM
    Tobias, H
    Bodenheimer, HC
    HEPATOLOGY, 1999, 30 (04) : 192A - 192A
  • [25] The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa-2B in combination with ribavirin.
    McHutchison, JG
    Poynard, T
    Harvey, J
    Garaud, JJ
    Albrecht, JK
    HEPATOLOGY, 2000, 32 (04) : 223A - 223A
  • [26] EFFECT OF INTERFERON ALFA-2B PLUS RIBAVIRIN THERAPY ON INCIDENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS
    Kurokawa, Mika
    Hiromotsu, Nooki
    Takeharo, Tetsuo
    Ozel, Tsugiko
    Yakushijin, Takayuki
    Igura, Takumi
    Mochizuki, Kiyoshi
    Imonaka, Kazuho
    Oshita, Mosohide
    Hagiwara, Hideki
    Mita, Eiji
    Hijiok, Taizo
    Inui, Yoshiaki
    Katayama, Kazuhiro
    Yoshihara, Horumosa
    Imai, Yosuharu
    Kato, Michio
    Kiso, Shinichi
    Kanto, Tatsuya
    Kasahoara, Akinori
    Hayashil, Norio
    HEPATOLOGY, 2008, 48 (04) : 880A - 881A
  • [27] HISTOLOGICAL OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS-C GIVEN A 60-WEEK INTERFERON ALFA-2B TREATMENT COURSE
    REICHARD, O
    GLAUMANN, H
    NORKRANS, G
    WEJSTAL, R
    FRYDEN, A
    SCHVARCZ, R
    WEILAND, O
    LIVER, 1994, 14 (04): : 169 - 174
  • [28] Pegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B
    Kaymakoglu, Sabahattin
    Oguz, Dilek
    Gur, Gurden
    Gurel, Selim
    Tankurt, Ethem
    Ersoz, Galip
    Ozenirler, Seren
    Kalayci, Cem
    Poturoglu, Sule
    Cakaloglu, Yilmaz
    Okten, Atilla
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (08) : 3020 - 3022
  • [29] A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
    Glue, P
    Rouzier-Panis, R
    Raffanel, C
    Sabo, R
    Gupta, SK
    Salfi, M
    Jacobs, S
    Clement, RP
    HEPATOLOGY, 2000, 32 (03) : 647 - 653
  • [30] Induction of Autoimmune Hepatitis by Pegylated Interferon Alfa-2b in Chronic Hepatitis C
    Loerke, Julia
    Erhardt, Andreas
    Haeussinger, Dieter
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (12) : A20 - A20
12345